Abemaciclib

證據等級: L5

預測適應症: 0 個

ABEMACICLIB: Drug Repurposing Evaluation Report

One-Sentence Summary

Abemaciclib is a selective CDK4/6 inhibitor, originally developed for the treatment of HR-positive, HER2-negative breast cancer (brand name: Verzenio). The TxGNN model has not yet generated any predicted new indications for this drug, and there are currently no clinical trials or publications linked to a repurposing hypothesis in this evidence pack.

Quick Overview

Item	Content
Original Indication	Not listed in evidence pack (known: HR+/HER2− breast cancer)
Predicted New Indication	— None predicted
TxGNN Prediction Score	— N/A
Evidence Level	L5 (No model prediction or supporting studies available)
Taiwan Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on publicly known information, Abemaciclib (DB12001) is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By blocking CDK4/6, it prevents phosphorylation of the retinoblastoma protein (Rb), halting cell cycle progression from G1 to S phase. This mechanism is particularly relevant in cancers driven by dysregulated CDK4/6–cyclin D–Rb signalling, most notably HR-positive, HER2-negative breast cancer.

No new indications have been predicted by TxGNN at this time. Without a target disease, it is not possible to evaluate mechanistic plausibility for repurposing. The absence of a prediction may reflect insufficient data in the knowledge graph, or that Abemaciclib's pharmacological profile did not meet the model's threshold for any novel indication in this run.

To enable a meaningful repurposing evaluation, the TxGNN prediction pipeline should be re-run once the knowledge graph is enriched with Abemaciclib's complete target, pathway, and indication data.

Clinical Trial Evidence

Currently no related clinical trials registered in the evidence pack for a repurposing indication.

Literature Evidence

Currently no related literature available in the evidence pack for a repurposing indication.

Taiwan Market Information

Abemaciclib is not currently marketed in Taiwan and holds 0 TFDA authorizations. No license records are available.

Cytotoxicity

Abemaciclib is an antineoplastic agent (CDK4/6 inhibitor class). The following information is based on the known pharmacological profile:

Item	Content
Cytotoxicity Classification	Targeted therapy (CDK4/6 inhibitor)
Myelosuppression Risk	High — neutropenia is the most common Grade ≥3 adverse event; thrombocytopenia also reported
Emetogenicity Classification	Low to moderate (diarrhoea is more clinically significant than emesis)
Monitoring Items	CBC with differential (every 2 weeks for first 2 months, then monthly), liver function tests (ALT, AST, bilirubin), renal function, signs of venous thromboembolism and interstitial lung disease
Handling Protection	Standard oral anticancer drug handling; not a conventional cytotoxic — no special closed-system transfer device required, but follow institutional oral hazardous drug policies

Safety Considerations

Safety data (key warnings, contraindications, and drug-drug interactions) was not available in the evidence pack for Abemaciclib.

Please refer to the package insert for safety information. Key known concerns from global labelling include: diarrhoea (dose-limiting toxicity), neutropenia, hepatotoxicity, venous thromboembolism, and interstitial lung disease/pneumonitis. Abemaciclib is a CYP3A4 substrate — concomitant strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) require dose reduction.

Conclusion and Next Steps

Decision: Hold

Rationale: No new indication has been predicted by TxGNN, and the evidence pack contains critical data gaps (MOA, TFDA package insert warnings, original indication mapping). Without a repurposing hypothesis, there is no actionable evaluation to advance.

To proceed, the following is needed:

Re-run TxGNN prediction with enriched knowledge graph data for Abemaciclib (targets: CDK4, CDK6; pathways: Rb/E2F cell cycle control)
Fill MOA data gap (DG002): Query DrugBank API for complete mechanism of action, targets, and pathway information
Fill TFDA safety data gap (DG001): Download and parse TFDA package insert PDF for warnings and contraindications — this is a blocking gap for Stage 1 safety assessment
Confirm Taiwan regulatory status: Verify whether Abemaciclib (Verzenio) has pending TFDA applications or is available through special import programmes
Once a predicted indication is available, re-generate this report with full evidence assessment
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.